Enabling happier and healthier lives.
Our vision
Humankind is still suffering from diseases that are considered incurable.
We design and discover medicines for these incurable diseases through event-driven pharmacology by leveraging AI to design much-needed medicines.
We envision a society where patients and physicians have precise control of pathogenic human protein concentrations via small molecules.
Our mission
We will bring multiple first-in-class small molecule degraders to the market by 2035 to enhance people’s lives.
We developed our CelerisTx One™ platform to design and test drugs in an AI-enabled Direct-To-Biology cycle to design and automate.
Our platform is a holistic solution to design the components necessary to induce degradation. CelerisTx One™ automates subsequent chemical and biological tasks before proceeding through multiple design-make-test iterations to develop medicines for high unmet medical needs.
Driven by people.
Leadership
Jakob Hohenberger 
CFO/COO, Co-Founder and Director
Dr. Chris Tame
VP, Head of Drug Discovery
Dr. Rosa Cookson
Head of Chemical Biology
Dr. Andrew Potterton
Head of Technology Platform
Dr. Adam Yip
Head of Exploratory
Board of Directors and Advisory
Dr. Peter Ho
Board Director
Karel Kubias
Board Director
Dr. James Field
Board Director
Dr. John Harling
Chair of the Sc. Advisory Board
Former Senior Sc. Director at GSK
